Wedbush Has Bullish Forecast for CMPX FY2024 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities research analysts at Wedbush raised their FY2024 EPS estimates for Compass Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.32) per share for the year, up from their previous forecast of ($0.39). Wedbush has a “Outperform” rating and a $8.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at $0.31 EPS and FY2028 earnings at $1.76 EPS.

CMPX has been the subject of several other research reports. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $5.00 to $4.00 in a research report on Friday. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Monday, November 11th. Finally, LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Monday, September 16th.

Compass Therapeutics Stock Down 13.2 %

Shares of NASDAQ:CMPX opened at $1.38 on Friday. The firm has a fifty day simple moving average of $1.75 and a two-hundred day simple moving average of $1.42. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.34. The stock has a market capitalization of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rovin Capital UT ADV purchased a new position in Compass Therapeutics in the 3rd quarter worth about $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics in the 3rd quarter worth about $30,000. XTX Topco Ltd purchased a new position in shares of Compass Therapeutics during the third quarter worth approximately $37,000. Cubist Systematic Strategies LLC bought a new stake in shares of Compass Therapeutics during the second quarter valued at approximately $41,000. Finally, Panagora Asset Management Inc. purchased a new stake in shares of Compass Therapeutics in the second quarter valued at approximately $68,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.